Revenue from operations rose 16% to Rs 2,101 crore, driven by robust performance in domestic and international businesses. The company’s EBITDA margins for April-June stood at 19.2% with EBITDA up 20.1% YoY.
International business grew 22%, while the rest of the world business grew 42%. The company’s Canada business grew 16.4% led by new launches and market share gains. Europe saw early benefits of new launches and grew 12.8%.
“We continue to augment our portfolio in all our focus markets through in-licensing and in-house development,” said Satish Mehta, CEO and managing director, Emcure Pharmaceuticals.
Its domestic business grew 9.4% led by strong performance in all out key therapies and aided by new initiatives in derma and OTC.
During the quarter, the company strengthened its domestic business through expansion of its strategic partnership with Sanofi. Going forward, Emcure will be marketing and distributing Sanofi’s oral anti-diabetic portfolio in addition to the cardiovascular portfolio.“The expanded Sanofi partnership positions us well in the fast-growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets, which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins,” Mehta said.Shares of Emcure Pharmaceuticals closed 1.58% lower at Rs 1,398.80 apiece on the BSE on Thursday. The company announced the earnings during market hours.
